NO743260L - - Google Patents
Info
- Publication number
- NO743260L NO743260L NO743260A NO743260A NO743260L NO 743260 L NO743260 L NO 743260L NO 743260 A NO743260 A NO 743260A NO 743260 A NO743260 A NO 743260A NO 743260 L NO743260 L NO 743260L
- Authority
- NO
- Norway
- Prior art keywords
- salt
- chloro
- tryptophan
- water
- organic solvent
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 19
- 239000011575 calcium Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 229910052782 aluminium Inorganic materials 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 11
- 229960004799 tryptophan Drugs 0.000 claims description 9
- 229910052749 magnesium Inorganic materials 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- IJWMYYIUFNJDKN-UHFFFAOYSA-N (4-chlorophenyl)methyl carbonochloridate Chemical compound ClC(=O)OCC1=CC=C(Cl)C=C1 IJWMYYIUFNJDKN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- -1 p-chloro-benzoxy Chemical group 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229940001593 sodium carbonate Drugs 0.000 claims 1
- 235000017550 sodium carbonate Nutrition 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 159000000000 sodium salts Chemical class 0.000 description 13
- 230000000694 effects Effects 0.000 description 9
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 5
- 159000000007 calcium salts Chemical class 0.000 description 5
- 239000003610 charcoal Substances 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 230000001262 anti-secretory effect Effects 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000002921 anti-spasmodic effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229960000905 indomethacin Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- HFZWRUODUSTPEG-UHFFFAOYSA-N 2,4-dichlorophenol Chemical compound OC1=CC=C(Cl)C=C1Cl HFZWRUODUSTPEG-UHFFFAOYSA-N 0.000 description 1
- ISNMKURUTRDPMG-UHFFFAOYSA-N 2-[(4-chlorophenyl)methoxycarbonylamino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)OCC1=CC=C(Cl)C=C1 ISNMKURUTRDPMG-UHFFFAOYSA-N 0.000 description 1
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000031320 Teratogenesis Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 150000001805 chlorine compounds Chemical group 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000007665 chronic toxicity Effects 0.000 description 1
- 231100000160 chronic toxicity Toxicity 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical group OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39705173A | 1973-09-13 | 1973-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO743260L true NO743260L (nl) | 1975-04-07 |
Family
ID=23569669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO743260A NO743260L (nl) | 1973-09-13 | 1974-09-11 |
Country Status (17)
| Country | Link |
|---|---|
| JP (1) | JPS5231923B2 (nl) |
| AT (1) | AT338258B (nl) |
| AU (1) | AU468784B2 (nl) |
| BE (1) | BE819650A (nl) |
| CA (1) | CA1028332A (nl) |
| CH (1) | CH614195A5 (nl) |
| DE (1) | DE2442303A1 (nl) |
| ES (1) | ES429988A1 (nl) |
| FI (1) | FI58913C (nl) |
| FR (1) | FR2243691B1 (nl) |
| GB (1) | GB1433679A (nl) |
| HK (1) | HK38779A (nl) |
| HU (1) | HU168975B (nl) |
| NL (1) | NL7411211A (nl) |
| NO (1) | NO743260L (nl) |
| SE (1) | SE399885B (nl) |
| ZA (1) | ZA745448B (nl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55130556U (nl) * | 1979-03-09 | 1980-09-16 | ||
| JPS6314144Y2 (nl) * | 1979-03-16 | 1988-04-20 | ||
| BR112022023734A2 (pt) * | 2020-05-24 | 2023-02-07 | Galimedix Therapeutics Inc | Formas cristalinas de solvatos de derivados de triptofano, composições que as compreendeem e usos das mesmas |
-
1974
- 1974-08-02 AU AU72870/74A patent/AU468784B2/en not_active Expired
- 1974-08-22 NL NL7411211A patent/NL7411211A/nl unknown
- 1974-08-23 GB GB3722474A patent/GB1433679A/en not_active Expired
- 1974-08-26 ZA ZA00745448A patent/ZA745448B/xx unknown
- 1974-08-28 FI FI2520/74A patent/FI58913C/fi active
- 1974-09-04 DE DE2442303A patent/DE2442303A1/de not_active Withdrawn
- 1974-09-06 BE BE148301A patent/BE819650A/xx not_active IP Right Cessation
- 1974-09-09 SE SE7411375A patent/SE399885B/xx unknown
- 1974-09-11 NO NO743260A patent/NO743260L/no unknown
- 1974-09-11 AT AT733774A patent/AT338258B/de not_active IP Right Cessation
- 1974-09-11 CH CH1234174A patent/CH614195A5/xx not_active IP Right Cessation
- 1974-09-12 ES ES429988A patent/ES429988A1/es not_active Expired
- 1974-09-12 JP JP49105439A patent/JPS5231923B2/ja not_active Expired
- 1974-09-12 FR FR7430928A patent/FR2243691B1/fr not_active Expired
- 1974-09-12 CA CA209,032A patent/CA1028332A/en not_active Expired
- 1974-09-12 HU HURO800A patent/HU168975B/hu unknown
-
1979
- 1979-06-14 HK HK387/79A patent/HK38779A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI58913B (fi) | 1981-01-30 |
| BE819650A (fr) | 1974-12-31 |
| NL7411211A (nl) | 1975-03-17 |
| SE7411375L (nl) | 1975-03-14 |
| HU168975B (nl) | 1976-08-28 |
| HK38779A (en) | 1979-06-22 |
| FI58913C (fi) | 1981-05-11 |
| DE2442303A1 (de) | 1975-03-27 |
| FR2243691A1 (nl) | 1975-04-11 |
| CA1028332A (en) | 1978-03-21 |
| ZA745448B (en) | 1975-09-24 |
| FI252074A (nl) | 1975-03-14 |
| JPS5058065A (nl) | 1975-05-20 |
| AT338258B (de) | 1977-08-10 |
| GB1433679A (en) | 1976-04-28 |
| JPS5231923B2 (nl) | 1977-08-18 |
| AU468784B2 (en) | 1976-01-22 |
| ES429988A1 (es) | 1976-09-16 |
| ATA733774A (de) | 1976-12-15 |
| AU7287074A (en) | 1976-01-22 |
| FR2243691B1 (nl) | 1978-02-03 |
| CH614195A5 (en) | 1979-11-15 |
| SE399885B (sv) | 1978-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4016268A (en) | Method of combatting gastric ulceration | |
| JPS59163400A (ja) | ウルソデソキシコ−ル酸硫酸エステルのナトリウム塩 | |
| US4455305A (en) | Composition for the treatment of colitis ulcerosa, enteritis regionalis crohn (morbus crohn), chronic nonspecific colitis and diverticulitis and the use of salicylazobenzoic acid for the preparation of such compositions | |
| PT79604B (en) | Treatment of hypertension compounds and compositions for antihypertension and diuresis | |
| JPH059424B2 (nl) | ||
| NO743260L (nl) | ||
| IL32889A (en) | Pyrido(4,3-b)indole derivatives,their preparation and pharmaceutical compositions containing them | |
| US4000297A (en) | N-p-chlorobenzoyl tryptophane, salts and compositions thereof | |
| US5747521A (en) | N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic acid ester, and pharmaceutical preparation containing the same | |
| US4939164A (en) | Strontium salt | |
| JPS58201713A (ja) | 製薬組成物およびその製造方法 | |
| US3002886A (en) | Betaine salicylates and the method for their preparation | |
| JPH04230326A (ja) | 非ステロイド系抗炎症療法における改良 | |
| JPH0365338B2 (nl) | ||
| EP0133423A1 (en) | Use of 4,5'-azo-bis-salicylic acid for the manufacture of a medicament for the treatment of inflammatory disorders in the intestine | |
| JPS5951954B2 (ja) | インド−ル酢酸イソベンゾフラニルエステル、その製造方法及びそれを含有する鎮痛及び抗炎症剤 | |
| JPS61280451A (ja) | 新規なアセチルサリチル酸誘導体、それの製法およびそれを含有している製薬学的組成物類 | |
| US3714363A (en) | Substituted amino guanidine as anti-diabetic agents | |
| US4447437A (en) | Pharmaceutical composition and method for treatment of peptic ulcer | |
| US4148912A (en) | Pharmaceutical compositions and methods of using the same | |
| AU614541B2 (en) | Choline diethyldithiocarbamate, a process for its preparation and therapeutic composition containing it | |
| US3155579A (en) | Therapeutic composition for the treatment of disturbances of the water metabolism characterized by an insufficient elmination of water | |
| RU2395282C2 (ru) | Лекарственная субстанция для подавления геликобактероподобных эрозивно-язвенных повреждений слизистой оболочки желудка | |
| US4267189A (en) | Method of use and composition for 1,3-dihydro-3-(2-hydroxy-2-methylpropyl)-2H-isoindol-1-one | |
| US3135659A (en) | Hydroxy and alkoxy aryl quinazolinones |